All News

artangiogca.jpg

ACR/Vasculitis Foundation Guideline for Giant Cell Arteritis and Takayasu Arteritis

Jack Cush, MD

The ACR and the Vasculitis Foundation have published their evidence-based recommendations and expert guidance for the management of GCA and Takayasu arteritis. These recommendations address a variety of clinical questions and scenarios including diagnostic testing, imaging, treatments, and surgical interventions. Recommendations for GCA and TAK include support for the use of glucocorticoid-sparing immunosuppressive agents and the use of imaging to identify large vessel involvement. Recommendations for TAK include the use of glucocorticoids as initial therapy.

Read Article
ANCA, vasculitis, test

ACR/Vasculitis Foundation 2021 Guidelines for ANCA–Associated Vasculitis

Jack Cush, MD

Chung et al have published the 2021 treatment guielines for the management of antineutrophil cytoplasmic antibody–associated vasculitis, including granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis. These guidelines are put forth by the ACR and the Vasculitis Foundation as benchmark guidance to assist health care professionals in managing AAV.  

Read Article
RheumNow Podcast square

RheumNow Podcast – Modern Treatment of RA Pregnancy (6.25.2021)

Jack Cush, MD

Dr. Jack Cush reviews this week’s news and journal reports featured on RheumNow.com.

Read Article
RheumNow Podcast square

RheumNow Podcast - Best of EULAR 2021

Jack Cush, MD

Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.

Read Article
Drugs capable of inducing drug-associated ANCA vasculitis - mirabegron (Myrbetriq), sofosbuvir (Sovaldi, antiviral), nintedanib (Ofev), hydralazine, propylthiouracil, thiamazole, minocycline, carbimazole, allopurinol, influenza vax.... https://t.co/KhK2w10hs5

Links:

Dr. John Cush RheumNow ( View Tweet)

ACR/Vasculitis Foundation 2021 Guidelines for ANCA–Associated Vasculitis Chung et al have published the 2021 treatment guidelines for the management of antineutrophil cytoplasmic antibody–AAV, including GPA, MPA, and EGPA. https://t.co/234OQ7klRd https://t.co/33sWq1U55T

Links:

Dr. John Cush RheumNow ( View Tweet)
Plasmapheresis Indications : TTP, HUS, Cryoglobulinemia, Hyperviscosity, Myasthenia gravis, Goodpastures, Catastrophic APL Syn, Chr inflamm demyelinating polyneuropathy, Removal of drugs/toxins, Alveolar hemorrhage, ANCA vasculitis (questionable) https://t.co/uph9Eprlvc https://t.co/FPLOgzZpfB

Links:

Dr. John Cush RheumNow ( View Tweet)
Textbooks say fever is common in lupus ("36%–86%") BUT IT IS NOT! Lupus is cause of FUO in 5%; Fever is seen in a minority of SLE onsets; Fever occurs w/ SLE complications - vasculitis, pneumonitis/serositis/alveolar hem, CNS, & INFECTION! https://t.co/KvZeo6Q1WY

Links:

Dr. John Cush RheumNow ( View Tweet)

WATCH: Is blindness with Tocilizumab in GCA a worry? Dr. David Liew ( @drdavidliew) weighs in. #EULAR2021 https://t.co/eFrmbkW9Gy https://t.co/imMaEIczb8

Links:

Dr. John Cush RheumNow ( View Tweet)
Blindness with Tocilizumab in GCA: Is it a Worry? https://t.co/PJYap294jm https://t.co/q1izGlH68j

Links:

Dr. John Cush RheumNow ( View Tweet)
Danish population study shows that all cause mortality in GCA is increased 49%,(RR 1.49; CI1.36-1.64) after 1 year but less so at 10 years (RR 1.03: 1.00-1.05). Deaths usually due to infectious, endocrine, cardiovascular, GI diseases https://t.co/p36zDskf6y

Links:

Dr. John Cush RheumNow ( View Tweet)

French Vasculitis registry studied 354 GPA patients- 25% had hypereosinophilia (HE) ≥ 500; mostly male (73%) w/ most skin dz (49%) peripheral neuropathy (32%) & higher BVAS (21 vs 18, p= 0.01): severe HE had more baseline renal dysfunction https://t.co/G4s3CEavL9

Links:

Dr. John Cush RheumNow ( View Tweet)

Rituximab in PMR. Intriguing proof of concept (SB?) RCT (1:1, total n=47 (recent dx 38/relapsing 9)) 17w rapid PNL taper ritux 1g x1 21w: steroid-free remission: 48% v 21% PNL ≤5mg/d: 100% v 54% effect mainly from recent dx pts We do need options! POS0343 #EULAR2021 @RheumNow https://t.co/g6xJekY92O
David Liew drdavidliew ( View Tweet)
Dr Schapp on nasal Staph Aureus eradication in ANCA vasculitis. Neither the presence or eradication of Staph Aureus appeared to influence the vasculitis @RheumNow #EULAR2021 Abstr#POS0249 https://t.co/bxtaznejNk
Richard Conway RichardPAConway ( View Tweet)
Dr Marsman presents positive RCT of Rituximab in PMR. GC-free remission 48% vs 21% (p=0.049) GC<=5mg 100% vs 47% (p=0.005) @RheumNow #EULAR2021 Abstr#POS0343 https://t.co/tjkKTS6DMN
Richard Conway RichardPAConway ( View Tweet)
Blindness with Tocilizumab in GCA: Is it a Worry? Dr. David Liew ( @drdavidliew ) #EULAR2021 https://t.co/xokPqGMEyA https://t.co/NJ3PrFR6nF

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheum alliance trainee survey (n=302): 87-96% report negative impact of COVID19 on Rheumatology training: -outpatient clinics (79%) -inpatient consultations (59%) -formal teaching (55%) -procedures (53%) and -ultrasonography (36%) #POS0051 @RheumNow #EULAR2021 @kristenyoung

Aurelie Najm AurelieRheumo ( View Tweet)

So it comes down to the grand question: how on earth do we actually monitor disease activity?? "We still don't have a failsafe algorithm... relapse is both underdiagnosed & overdiagnosed" - @Sarah_L_Mackie The challenge lots of good people are working on! #EULAR2021 @RheumNow https://t.co/PUa6Ly1DQw
David Liew drdavidliew ( View Tweet)
Drug-induced ANCA-associated vasculitis: here are the ones to look for👇 - hydralazine - PTU - penicillamine - thiamazole - sofosbuvir - minocycline - carbimazole (but then a few others floating about!) VigiBase data POS0118 #EULAR2021 @RheumNow https://t.co/ujgJAJQeKY
David Liew drdavidliew ( View Tweet)
Fascinating talk by Dr Tombetti on the potential use of arterial wall derived microvesicles collected from plasma as a means of non-invasive liquid biopsy in vasculitis @RheumNow #EULAR2021 Abstr#OP0056 https://t.co/Y6UO2mpjV0
Richard Conway RichardPAConway ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×